本文選題：卵巢上皮性腫瘤 + IL-17A　； 參考：《天津醫(yī)科大學(xué)》2014年碩士論文

【摘要】：目的： 1.檢測(cè)IL-17A和IL-17F在卵巢上皮性腫瘤及正常卵巢組織中的表達(dá)。 2.分析IL-17A和IL-17F與卵巢上皮性腫瘤各種臨床病理參數(shù)和腫瘤微血管生成的關(guān)系,并初步探討其可能機(jī)制。 3.評(píng)估IL-17A和IL-17F對(duì)患者預(yù)后的影響。 方法： 1.收集76例惡性卵巢上皮性腫瘤、10例交界性卵巢上皮性腫瘤、10例良性卵巢上皮性腫瘤和10例宮頸癌手術(shù)中切除的正常卵巢組織,采用免疫組織化學(xué)的方法,觀察IL-17A和IL-17F的表達(dá)和分布特征。 2.采用免疫組織化學(xué)的方法對(duì)血管內(nèi)皮細(xì)胞標(biāo)志物CD105進(jìn)行染色,計(jì)數(shù)惡性卵巢上皮性腫瘤中微血管的生成,探討其與IL-17A、IL-17F表達(dá)的相關(guān)性。 3.統(tǒng)計(jì)分析IL-17A、IL-17F表達(dá)與臨床資料的關(guān)系,并對(duì)隨訪資料進(jìn)行生存分析。 結(jié)果： 1.惡性卵巢上皮性腫瘤組織中IL-17A、IL-17F呈高表達(dá),且IL-17A與CD105(CD105標(biāo)記血管內(nèi)皮細(xì)胞計(jì)數(shù)MVD)的表達(dá)呈正相關(guān)(r=0.326, P0.05), IL-17F與CD105的表達(dá)呈負(fù)相關(guān)(r=-0.232,P0.05)。 2.IL-17A. IL-17F在卵巢癌組織中的表達(dá)與組織學(xué)分級(jí)、有無(wú)遠(yuǎn)處轉(zhuǎn)移和有無(wú)淋巴結(jié)轉(zhuǎn)移呈正相關(guān)(P0.05),而與患者年齡、腫瘤大小、病理分型、有無(wú)腹水無(wú)相關(guān)性(P0.05)。 3.卵巢癌組織中,IL-17A表達(dá)陽(yáng)性組MVD值(4.95±1.91)明顯高于陰性組(3.71±1.87)(P0.05), IL-17F表達(dá)陽(yáng)性組MVD值(4.06-4-1.91)明顯低于陰性組(5.22+2.23)(P0.05)。 4.單因素生存分析顯示,組織學(xué)分級(jí)Ⅲ-Ⅳ級(jí)組平均生存時(shí)間較Ⅰ～Ⅱ級(jí)組平均生成時(shí)間短(P0.05);有遠(yuǎn)處轉(zhuǎn)移組平均生存時(shí)間較無(wú)遠(yuǎn)處轉(zhuǎn)移組平均生存時(shí)間短(P0.05);有淋巴結(jié)轉(zhuǎn)移組平均生存時(shí)間較無(wú)淋巴結(jié)轉(zhuǎn)移組平均生存時(shí)間短(P0.05)；IL-17A高表達(dá)組平均生存時(shí)間較低表達(dá)組平均生存時(shí)間短(P0.01)；IL-17F高表達(dá)組平均生存時(shí)間較低表達(dá)組平均生存時(shí)間短(P0.01)。多因素生存分析顯示,IL-17A蛋白表達(dá)、IL-17F蛋白表達(dá)、組織學(xué)分級(jí)是影響惡性卵巢上皮腫瘤患者預(yù)后的獨(dú)立因素(P0.05)。 結(jié)論： 1. IL-17A、IL-17F在卵巢上皮性腫瘤組織中的表達(dá)與腫瘤的惡性程度有關(guān),腫瘤的惡性程度越高,IL-17A和IL-17F表達(dá)的陽(yáng)性率越高。在卵巢上皮性腫瘤的發(fā)生、發(fā)展中起重要作用,可以作為臨床判斷卵巢上皮性腫瘤生物學(xué)行為有用的分子生物學(xué)指標(biāo)。 2.IL-17A可發(fā)揮促卵巢癌微血管生成的作用,而IL-17F可發(fā)揮抑制微血管生成的作用,二者通過(guò)調(diào)節(jié)促血管生成和抗血管生成的平衡來(lái)促進(jìn)腫瘤微血管的生成,且可作為預(yù)測(cè)卵巢上皮性腫瘤患者預(yù)后的獨(dú)立危險(xiǎn)因素。
[Abstract]:Objective: 1. The expression of IL-17A and IL-17F in epithelial ovarian tumors and normal ovarian tissues was detected. 2. To analyze the relationship between IL-17A and IL-17F and various clinicopathological parameters and microangiogenesis of ovarian epithelial tumors, and to explore its possible mechanism. 3. To evaluate the influence of IL-17A and IL-17F on the prognosis of patients. Methods: 1. Ten cases of borderline epithelial ovarian tumors and 10 cases of benign ovarian epithelial tumors and 10 cases of normal ovarian tissues were collected from 76 cases of malignant ovarian epithelial tumors and 10 cases of cervical cancer. The expression and distribution of IL-17A and IL-17F were observed. 2. Immunohistochemical staining of vascular endothelial cell marker (CD105) was used to count the formation of microvessels in malignant ovarian epithelial tumors and to explore its correlation with the expression of IL-17An IL-17F. 3. To analyze the relationship between the expression of IL-17 and clinical data, and to analyze the survival of follow-up data. Results: 1. In malignant ovarian epithelial tumors, IL-17An IL-17F expression was highly expressed, and the expression of IL-17A was positively correlated with the expression of CD105(CD105 labeled vascular endothelial cells (MVD) 0.326, P0.05, and IL-17F was negatively correlated with the expression of CD105. 2.IL-17A. The expression of IL-17F in ovarian carcinoma was positively correlated with histological grade, distant metastasis and lymph node metastasis (P 0.05), but had no correlation with age, tumor size, pathological type and ascites. 3. In ovarian cancer, the MVD value of the positive group was 4.95 鹵1.91) and the MVD value of the positive group of IL-17F expression was 4.06-4-1.91), which was significantly higher than that of the negative group (3.71 鹵1.87), and the MVD value of the positive group of IL-17F expression was significantly lower than that of the negative group (5.22 2.23 P 0.05). 4. Univariate survival analysis showed that, Histological grade 鈪，

本文編號(hào)：1882731